注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Cingulate Inc是一家臨床階段的生物製藥公司。該公司專注於利用精確定時釋放(PTR)藥物輸送平台技術開發,製造和商業化藥品,以創建劑量計劃和藥物釋放曲線,改善患有多種常見疾病的患者的生活。該公司專注於注意力缺陷/多動障礙(ADHD)的治療。該公司正在開發兩種主要候選產品,如CTx-1301(右哌甲酯)和CTx-1302(右旋安非他明)。其CTx-1301和CTx-1302候選藥物均含有三種釋放的活性藥物成分,組合成一種小片劑型。其CTx-1301和CTx-1302正在開髮用於治療ADHD的三個核心患者部分:兒童(6-12歲),青少年(13-17歲)和成人(18歲以上)。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Brian D. Barash | - | - | Member of Scientific Advisory Board |
Andrew J. Cutler | - | - | Member of Scientific Advisory Board |
John S. Markowitz | - | - | Member of Scientific Advisory Board |
Alice Mao | - | - | Member of Scientific Advisory Board |
Ann Childress | - | - | Member of Scientific Advisory Board |
Sharon B. Wigal | - | - | Member of Scientific Advisory Board |
Peter J. Werth | 84 | 2018 | Director |
Declan Quinn | - | - | Member of Scientific Advisory Board |
Ignacio Herman Valdes | - | - | Member of Scientific Advisory Board |
Dinohra Munoz-Silva | - | - | Member of Scientific Advisory Board |
Jeffrey S. Ervin | 46 | 2024 | Director |
Bryan Jay Lawrence | 58 | 2024 | Director |
Jeffrey Newcorn | - | - | Member of Scientific Advisory Board |
Laurence L. Greenhill | - | - | Member of Scientific Advisory Board |
John A. Roberts | 65 | 2024 | Independent Director |
Shane J. Schaffer | 49 | 2012 | CEO & Chairman of the Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核